We then subdivided HCC patients with T2DM, we found that In the subgroup of without T2DM, p-Ser9-GSK-3β over-expressing patients had higher recurrence rates(1-,3-,and 5-year recurrence rates: 45.5%, 64.8% and 83.3% vs. 23.0%, 42.4%, and 57.1%, P = 0.004), and lower survival rates(1-,3-,and 5-year survival rates: 78.4%, 49.3% and 24.4% vs. 87.6%, 72.4% and 60.7%, P<0.001) than those of under-expressing patients. The gene discussed is GSK3B; the disease is hepatocellular carcinoma.